CStone Pharmaceuticals Reports Strong 2026 Interim Results Amid Pipeline Expansion

CStone Pharmaceuticals released its 2026 interim financial results, highlighting accelerated progress in its drug development pipeline and sustained growth in international markets. The report underscores the company's strategic focus on expanding its commercial footprint while advancing clinical trials.